Evidence map›Paper›PMID 42137598›Full record

ArticleMolecular therapy. Advances2026

Gene therapy induces pigmentation in induced pluripotent stem cell-derived retinal pigment epithelium of OCA1A patients and albino rat eye.

Aman George, Arnold Leigh, Evan Selzer, Tyler Pfister, Charles DeYoung, Rafael Villasmil, Mones Abu-Asab, Suja Hiriyanna, Philsang Hwang, Ruchi Sharma and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aman GeorgePediatric Developmental & Genetic Ophthalmology Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Arnold LeighPediatric Developmental & Genetic Ophthalmology Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Evan SelzerPediatric Developmental & Genetic Ophthalmology Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Tyler PfisterPediatric Developmental & Genetic Ophthalmology Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Charles DeYoungPediatric Developmental & Genetic Ophthalmology Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Rafael VillasmilFlow Cytometry Core Facility, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Mones Abu-AsabElectron Microscopy Laboratory, Biological Imaging Core, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Suja HiriyannaOcular Gene Therapy Core, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Philsang HwangOcular Gene Therapy Core, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Ruchi SharmaOcular and Stem Cell Translational Research Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Arvydas MaminishkisTranslational Research CORE, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Tiansen LiOcular Gene Therapy Core, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.
Brian P BrooksPediatric Developmental & Genetic Ophthalmology Section, Ophthalmic Genetics & Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda MD 20892, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oculocutaneous albinism type 1A (OCA1A), the most severe and prevalent form of albinism, is caused by recessive mutations in the

Indexed as

albinismgene therapyinduced pluripotent stem cellsretinal pigment epitheliumtyrosinase

Identifiers

PMID42137598
PMCPMC13148931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.